Research Grant Request for Proposals: Research on Long-Acting Growth Hormone

Deadline: 11-Mar-2026

Pfizer’s Investigator Sponsored Research (ISR) Grants Program supports research projects exploring long-acting growth hormone (GH) therapies compared to daily GH. Grants of $50,000–$75,000 for one to two years are available to institutions in eligible regions, with a focus on clinical outcomes, adherence, pathophysiology, monitoring, and novel strategies for managing short stature.

Program Overview

Pfizer’s ISR Grants Program is designed to support investigator-led research that addresses data gaps and unmet medical needs in long-acting growth hormone treatment. The program encourages proposals that:

• Evaluate clinical effects and adherence of long-acting GH versus daily GH

• Study pathophysiology and real-world outcomes

• Explore novel monitoring and follow-up strategies

• Investigate innovative approaches to short stature management

The initiative aims to generate evidence that enhances clinical knowledge and improves treatment strategies for patients requiring GH therapy.

Grant Amount and Duration

• Funding per project: $50,000–$75,000

• Project duration: 1–2 years

• Number of grants: Four proposals selected

Who Is Eligible

Eligible applicants include:

• Institutions legally able to receive funding from Pfizer Inc.

• Principal Investigators affiliated with the applying institution

• Regions: APAC, Australia, Brazil, France, Greece, Italy, Israel, Japan, Saudi Arabia, Spain, Turkey, UAE, USA

Principal Investigator requirements:

• Must meet academic and professional qualifications defined by Pfizer

• Must lead the project and be affiliated with the applying institution

Research Focus Areas

Pfizer encourages proposals that address:

1. Clinical Outcomes and Effectiveness

   • Compare long-acting GH vs daily GH in real-world settings

   • Measure efficacy, safety, and patient-reported outcomes

2. Adherence and Treatment Management

   • Explore adherence rates and patterns

   • Evaluate follow-up and monitoring strategies

3. Pathophysiology and Mechanistic Insights

   • Study biological and metabolic effects of GH therapies

   • Examine long-term impact on growth and health

4. Novel Approaches to Unmet Needs

   • Propose innovative strategies for short stature management

   • Evaluate new clinical protocols or intervention models

How to Apply

Step 1: Confirm Eligibility

• Ensure the institution can legally receive funds from Pfizer

• Verify Principal Investigator affiliation and qualifications

Step 2: Develop Research Proposal

Include:

• Research objectives and hypotheses

• Study design, methodology, and metrics

• Expected outcomes and impact

• Timeline (1–2 years)

• Budget within $50,000–$75,000

Step 3: Prepare Institutional Documentation

• Institutional approval letters

• Principal Investigator CV and qualifications

• Compliance with local regulations and Pfizer requirements

Step 4: Submit Application

• Follow Pfizer’s application guidelines

• Submit all supporting documentation

• Adhere to deadlines

Selection Criteria

Applications are assessed based on:

• Scientific rigor and methodology

• Relevance to unmet needs in long-acting GH treatment

• Potential to advance clinical knowledge and improve patient outcomes

• Feasibility within proposed budget and timeline

• Investigator expertise and institutional support

Common Mistakes to Avoid

• Exceeding the $75,000 budget limit

• Submitting projects outside eligible regions

• Failing to demonstrate Principal Investigator affiliation

• Proposing studies without clear objectives or clinical relevance

• Omitting institutional approval or supporting documentation

Why This Grant Matters

Long-acting GH therapies are an evolving area in endocrinology. Evidence from investigator-led research can:

• Improve treatment adherence and patient outcomes

• Inform clinical guidelines and best practices

• Address unmet needs in short stature management

• Support innovative monitoring and follow-up strategies

Frequently Asked Questions (FAQ)

1. What is the funding range?

$50,000–$75,000 per project.

2. How long can projects last?

1–2 years.

3. Who can apply?

Institutions in eligible regions with a qualified Principal Investigator.

4. How many proposals will be funded?

Four proposals will be selected.

5. Can an independent researcher apply without institutional affiliation?

No. The Principal Investigator must be affiliated with an eligible institution.

6. Are international collaborations allowed?

Yes, provided the Principal Investigator and lead institution are in eligible regions.

7. What types of research are prioritized?

Clinical comparisons of long-acting vs daily GH, adherence studies, pathophysiology research, and innovative short stature management strategies.

Conclusion

Pfizer’s ISR Grants Program offers a strategic opportunity for institutions and qualified Principal Investigators to advance knowledge in long-acting growth hormone therapy. With funding of up to $75,000 per project, the initiative aims to generate impactful, investigator-led research that enhances clinical understanding and improves patient care worldwide.

For more information, visit Pfizer.